Share on StockTwits

Equities researchers at Stifel Nicolaus started coverage on shares of Kite Pharma (NASDAQ:KITE) in a research report issued on Tuesday. The firm set a “buy” rating and a $31.00 price target on the stock. Stifel Nicolaus’ price objective suggests a potential upside of 35.08% from the company’s current price.

Kite Pharma (NASDAQ:KITE) opened at 22.95 on Tuesday. Kite Pharma has a one year low of $21.00 and a one year high of $32.65. The stock’s 50-day moving average is $23.93 and its 200-day moving average is $24.81. The company’s market cap is $846.1 million.

KITE has been the subject of a number of other recent research reports. Analysts at Citigroup Inc. initiated coverage on shares of Kite Pharma in a research note on Tuesday, July 15th. They set an “outperform” rating and a $24.05 price target on the stock. Separately, analysts at Cowen and Company initiated coverage on shares of Kite Pharma in a research note on Tuesday, July 15th. They set an “outperform” rating on the stock. Finally, analysts at Credit Suisse initiated coverage on shares of Kite Pharma in a research note on Tuesday, July 15th. They set an “outperform” rating and a $34.00 price target on the stock. Five research analysts have rated the stock with a buy rating, Kite Pharma presently has an average rating of “Buy” and a consensus target price of $31.01.

Kite Pharma, Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of cancer immunotherapy products designed to harness the power of a patient’s own immune system to eradicate cancer cells.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.